title: Nuclear shape and prognosis following orchiectomy in stage D2 prostate cancer.
abstract: In this study, we have examined whether tumor grade and morphometric nuclear features can predict the outcome of treatment by orchiectomy in patients with stage D2 prostate cancer. Two outcome groups based on duration of survival postorchiectomy were examined, a bad outcome group of 63 patients who died from prostate cancer within 12 months and a good outcome group of 34 patients who survived beyond 5 years. Tumors were histologically classified as well (17%), moderate (17%), or poorly differentiated (66%). Tumor grade and patient outcome were significantly associated (Mann-Whitney test; P < 0.005), with 76% of poorly differentiated tumors in the bad outcome group, and 65% of well-differentiated tumors in the good outcome group. Using discriminant function analysis, tumor grade correctly predicted outcome in 70% of cases. A statistically significant difference was also detected in nuclear shape values between the two outcome groups (P < 0.05) and histological grades (P < 0.05). Using discriminant function analysis, 51% of cases were correctly classified into outcome groups using nuclear shape factors, a figure which rose to 65% when all nuclear morphometric features were used. This demonstrates that nuclear morphometric features are of no clinical value in predicting the outcome of treatment in stage D2 disease. Furthermore, these evaluations cannot select patients who might be spared orchiectomy on the basis of a predicted poor response. However, nuclear shape and variance measurements of benign glandular epithelial cells within cancerous prostates were significantly different from those of malignant cells (P < 0.005). We conclude that, while video image analysis of prostatic nuclear shape can reliably discriminate between benign and malignant cells, nuclear morphometric features are of minimal prognostic value in men with stage D2 prostate cancer treated by androgen ablation.
authors.affiliation: Department of Surgery, Flinders Medical Centre, Bedford Park, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Miller
authors.forename: D J
authors.initials: DJ
authors.lastname: Horsfall
authors.forename: J M
authors.initials: JM
authors.lastname: Skinner
authors.forename: D M
authors.initials: DM
authors.lastname: Rao
authors.forename: A S
authors.initials: AS
authors.lastname: Leong
authors.forename: V R
authors.initials: VR
authors.lastname: Marshall
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002467:Cell Nucleus / Q000473:pathology*; D004396:Coloring Agents; D016002:Discriminant Analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D012394:Rosaniline Dyes; D013194:Staining and Labeling; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D004396:Coloring Agents; C007722:Feulgen stain; D012394:Rosaniline Dyes